1031367-55-1

Basic information

• Product Name: C₂₄H₂₃NO₄
• Synonyms: C₂₄H₂₃NO₄
• CAS NO: 1031367-55-1
• Molecular Weight: 389.451
• Mol File: 1031367-55-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: C₂₄H₂₃NO₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₄H₂₃NO₄(1031367-55-1)
• EPA Substance Registry System: C₂₄H₂₃NO₄(1031367-55-1)

Safety Data

• Hazardous Substances Data: 1031367-55-1(Hazardous Substances Data)

Upstream product

• 58574-03-1 4'-Hydroxybiphenyl-4-carboxylic acid 
• 499239-74-6 C₁₃H₉ClO₂ 
• 1745-07-9 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 1031367-64-2 MC₇₀ 

Relevant articles and documents

Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier

P-Glycoprotein (P-gp), along with other transporter proteins at the blood-brain barrier (BBB), limits the entry of many pharmaceuticals into the brain. Altered P-gp function has been found in several neurological diseases. To study the P-gp function, many positron emission tomography (PET) radiopharmaceuticals have been developed. Most P-gp radiopharmaceuticals are labeled with carbon-11, while labeling with fluorine-18 would increase their applicability due to longer half-life. Here we present the synthesis and in vivo evaluation of three novel fluorine-18 labeled radiopharmaceuticals: 4-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-2-(4-fluorophenyl)oxazole (1a), 2-biphenyl-4-yl-2-fluoroethoxy-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline (2), and 5-(1-(2-fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen (3). Compounds were characterized as P-gp substrates in vitro, and Mdr1a/b(-/-)Bcrp1(-/-) and wild-type mice were used to assess the substrate potential in vivo. Comparison was made to (R)-[11C]verapamil, which is currently the most frequently used P-gp substrate. Compound [18F]3 was performing the best out of the new radiopharmaceuticals; it had 2-fold higher brain uptake in the Mdr1a/b(-/-)Bcrp1(-/-) mice compared to wild-type and was metabolically quite stable. In the plasma, 69% of the parent compound was intact after 45 min and 96% in the brain. Selectivity of [18F]3 to P-gp was tested by comparing the uptake in Mdr1a/b(-/-) mice to uptake in Mdr1a/b(-/-)Bcrp1(-/-) mice, which was statistically not significantly different. Hence, [18F]3 was found to be selective for P-gp and is a promising new radiopharmaceutical for P-gp PET imaging at the BBB. (Chemical Equation).

6,7-DIOXYALKYLTETRAHYDROISOQUINOLINE COMPOUNDS

The present invention relates to a 6,7-dioxyalkyltetrahydroisoquinoline compound, or a salt or solvate thereof according to formula I: (formula I), (I) wherein R represents hydrogen or a fluorinated alkyl group, and R2 and R3 independently represents hydrogen or an alkyl group.